JP6434528B2 - 置換ピリドン及びピラジノン、並びに好中球エラスターゼ活性の阻害剤としてのその使用 - Google Patents
置換ピリドン及びピラジノン、並びに好中球エラスターゼ活性の阻害剤としてのその使用 Download PDFInfo
- Publication number
- JP6434528B2 JP6434528B2 JP2016553397A JP2016553397A JP6434528B2 JP 6434528 B2 JP6434528 B2 JP 6434528B2 JP 2016553397 A JP2016553397 A JP 2016553397A JP 2016553397 A JP2016553397 A JP 2016553397A JP 6434528 B2 JP6434528 B2 JP 6434528B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- group
- cycloalkyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- GNFSIUKCNUCADV-UHFFFAOYSA-N O=C(c1c2cccc1)N(Cc(cc1)ccc1S)C2=O Chemical compound O=C(c1c2cccc1)N(Cc(cc1)ccc1S)C2=O GNFSIUKCNUCADV-UHFFFAOYSA-N 0.000 description 2
- 0 C*c1ccc(C*(C)(C)C(C2=*C(C(*c3ccc(*)cc3)=CC=*)=C(C)*(c3cccc(C(*)(N)N)c3)C2=O)=O)cc1 Chemical compound C*c1ccc(C*(C)(C)C(C2=*C(C(*c3ccc(*)cc3)=CC=*)=C(C)*(c3cccc(C(*)(N)N)c3)C2=O)=O)cc1 0.000 description 1
- BVDKOCOSYALVHV-UHFFFAOYSA-N CC(N(c1cc(C(F)(F)F)ccc1)C(C(C(NCc(cc1)ccc1S(C)NCCOC)=O)=C1)=O)=C1C(NC)=CC=N Chemical compound CC(N(c1cc(C(F)(F)F)ccc1)C(C(C(NCc(cc1)ccc1S(C)NCCOC)=O)=C1)=O)=C1C(NC)=CC=N BVDKOCOSYALVHV-UHFFFAOYSA-N 0.000 description 1
- YZEGZFZTMJEUEM-JRYSPGDBSA-N CC(N(c1cc(C(F)(F)F)ccc1)C(C(C(NCc(cc1)ccc1SC)=O)=C1)=O)=C1/C(/NC)=C/C=N Chemical compound CC(N(c1cc(C(F)(F)F)ccc1)C(C(C(NCc(cc1)ccc1SC)=O)=C1)=O)=C1/C(/NC)=C/C=N YZEGZFZTMJEUEM-JRYSPGDBSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N NCc1ccccc1 Chemical compound NCc1ccccc1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14156159 | 2014-02-21 | ||
| EP14156159.7 | 2014-02-21 | ||
| PCT/EP2015/053309 WO2015124563A1 (en) | 2014-02-21 | 2015-02-17 | Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509611A JP2017509611A (ja) | 2017-04-06 |
| JP2017509611A5 JP2017509611A5 (OSRAM) | 2018-03-29 |
| JP6434528B2 true JP6434528B2 (ja) | 2018-12-05 |
Family
ID=50137570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553397A Active JP6434528B2 (ja) | 2014-02-21 | 2015-02-17 | 置換ピリドン及びピラジノン、並びに好中球エラスターゼ活性の阻害剤としてのその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9221807B2 (OSRAM) |
| EP (1) | EP3107911B1 (OSRAM) |
| JP (1) | JP6434528B2 (OSRAM) |
| WO (1) | WO2015124563A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017207432A1 (en) * | 2016-05-31 | 2017-12-07 | Chiesi Farmaceutici S.P.A. | Novel compounds |
| AR108609A1 (es) * | 2016-05-31 | 2018-09-05 | Chiesi Farm Spa | Derivados de imidazolona y pirazolona como inhibidores de la elastasa de neutrófilos humana (hne) |
| PL3890828T3 (pl) * | 2018-12-03 | 2025-06-16 | Boehringer Ingelheim International Gmbh | Związki heteroaromatyczne jako inhibitory wanin |
| AU2020349353A1 (en) | 2019-09-17 | 2022-04-14 | Duke University | Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease |
| ES2962498T3 (es) | 2020-04-16 | 2024-03-19 | Mereo Biopharma 4 Ltd | Métodos que implican el inhibidor de elastasa de neutrófilos alvelestat para el tratamiento de enfermedades respiratorias mediadas por deficiencia de alfa-1 antitripsina |
| US20220242932A1 (en) * | 2021-01-29 | 2022-08-04 | DiaMedica USA Inc. | Ulinastatin polypeptides for treating diseases |
| KR20240090272A (ko) | 2021-10-20 | 2024-06-21 | 메레오 바이오파마 4 리미티드 | 섬유화 치료에 사용하기 위한 호중구 엘라스테이스 억제제 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200500341A (en) * | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0302487D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0605469D0 (en) * | 2006-03-17 | 2006-04-26 | Argenta Discovery Ltd | Multimers of heterocyclic compounds and their use |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| AU2010302420B2 (en) | 2009-10-02 | 2013-07-04 | Astrazeneca Ab | 2-pyridone compounds used as inhibitors of neutrophil elastase |
-
2015
- 2015-02-12 US US14/620,323 patent/US9221807B2/en active Active
- 2015-02-17 JP JP2016553397A patent/JP6434528B2/ja active Active
- 2015-02-17 WO PCT/EP2015/053309 patent/WO2015124563A1/en not_active Ceased
- 2015-02-17 EP EP15705807.4A patent/EP3107911B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20150239875A1 (en) | 2015-08-27 |
| EP3107911A1 (en) | 2016-12-28 |
| WO2015124563A1 (en) | 2015-08-27 |
| US9221807B2 (en) | 2015-12-29 |
| EP3107911B1 (en) | 2018-10-31 |
| JP2017509611A (ja) | 2017-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6434528B2 (ja) | 置換ピリドン及びピラジノン、並びに好中球エラスターゼ活性の阻害剤としてのその使用 | |
| ES2809974T3 (es) | Compuestos de indol carboxamida útiles como inhibidores de cinasas | |
| TWI451869B (zh) | 胺基二氫噻衍生物 | |
| JP6319747B2 (ja) | 置換４−ピリドン及びそれらの好中球エラスターゼ活性阻害薬としての使用 | |
| JP6278416B2 (ja) | 置換４−ピリドン及びそれらの好中球エラスターゼ活性阻害薬としての使用 | |
| EP2412708A1 (en) | Substituted 3-hydroxy-4-pyridone derivative | |
| JP2008526761A (ja) | 多環式ビス−アミドｍｍｐ阻害剤 | |
| WO2006022442A1 (ja) | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 | |
| EP2888248B1 (en) | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity | |
| JP2011518142A (ja) | Ｆａａｈ阻害剤として有用なエーテルベンジリデンピペリジン５員アリールカルボキサミド化合物 | |
| CA2900308A1 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
| TW200410963A (en) | Heterocyclic derivatives | |
| JP2011518143A (ja) | Ｆａａｈ阻害剤として有用なエーテルベンジリデンピペリジンアリールカルボキサミド化合物 | |
| JPWO2009041559A1 (ja) | インダゾールアクリル酸アミド化合物 | |
| CA2956745C (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
| ES2313319T3 (es) | 3-((hetero)arilsulfonil)-8-((aminoalkil)oxi)quinolinas como antagonistas del receptor 5-ht6 para el tratamiento del snc. | |
| HUP0104533A2 (hu) | Új pirimidinszármazékok és eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények | |
| BE1021252B1 (fr) | Nouveaux derives de 3-(indol-3-yl)-pyridine, compositions pharmaceutiques et methodes d'utilisation | |
| OA17445A (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
| HK1116164A (en) | [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-s-transferase and nadphquinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180213 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180213 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181016 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181011 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181108 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6434528 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |